Arvinas, Inc. (ARVN): Price and Financial Metrics


Arvinas, Inc. (ARVN)

Today's Latest Price: $27.29 USD

0.70 (-2.50%)

Updated Sep 21 11:20am

Add ARVN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 232 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARVN Stock Summary

  • Arvinas Inc's stock had its IPO on September 27, 2018, making it an older stock than only 3.99% of US equities in our set.
  • With a price/sales ratio of 23.4, Arvinas Inc has a higher such ratio than 93.43% of stocks in our set.
  • Revenue growth over the past 12 months for Arvinas Inc comes in at 216.07%, a number that bests 97.09% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Arvinas Inc, a group of peers worth examining would be CUE, ARWR, ZYME, CLLS, and ACRS.
  • ARVN's SEC filings can be seen here. And to visit Arvinas Inc's official web site, go to www.arvinas.com.
ARVN Daily Price Range
ARVN 52-Week Price Range

ARVN Stock Price Chart Technical Analysis Charts


ARVN Price/Volume Stats

Current price $27.29 52-week high $61.57
Prev. close $27.99 52-week low $15.19
Day low $26.83 Volume 132,402
Day high $27.58 Avg. volume 451,579
50-day MA $28.95 Dividend yield N/A
200-day MA $40.03 Market Cap 1.07B

Arvinas, Inc. (ARVN) Company Bio


Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.


ARVN Latest News Stream


Event/Time News Detail
Loading, please wait...

ARVN Latest Social Stream


Loading social stream, please wait...

View Full ARVN Social Stream

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

Hedge Funds Have Never Been This Bullish On Arvinas, Inc. (ARVN)

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]

Yahoo | September 15, 2020

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET. A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.About Arvinas Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, deve...

Yahoo | September 4, 2020

ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor

ESSA Pharma Inc. (NASDAQ:EPIX) [TSX-V: EPI] is a Canadian/U.S. clinical-stage pharmaceutical company which recently began Phase 1 clinical trials for its lead drug EPI-7386, a novel treatment for men with castration-resistant prostate cancer ("CRPC") where the cancer is progressing despite the men having been treated with current standard of care...

Steven Goldman on Seeking Alpha | August 19, 2020

IPO Update: Kymera Therapeutics Readies $125 Million IPO

Quick Take Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is advancing treatment candidates for skin and immune system conditions. KYMR is still some time away from beginning Phase 1 safety trials...

Donovan Jones on Seeking Alpha | August 17, 2020

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -12.07% and 0.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2020

Read More 'ARVN' Stories Here

ARVN Price Returns

1-mo 7.44%
3-mo -18.90%
6-mo -33.15%
1-year 11.43%
3-year N/A
5-year N/A
YTD -33.58%
2019 219.77%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ARVN

Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:

Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6805 seconds.